Drug Profile
Paridiprubart - Edesa Biotech
Alternative Names: EB 05; EB-07; NI-0101Latest Information Update: 31 Jul 2023
Price :
$50
*
At a glance
- Originator NovImmune SA
- Developer Edesa Biotech; Light Chain Bioscience
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III SARS-CoV-2 acute respiratory disease
- Phase II Rheumatoid arthritis
- Phase I Systemic scleroderma
Most Recent Events
- 10 Jul 2023 Edesa Biotech and US FDA agrees on primary endpoint for phase III trial in Adult respiratory distress syndrome
- 28 Jun 2023 Pharmacodynamics data from preclinical trial in SARS-COV-2 acute respiratory distress syndrome released by Edesa Biotech
- 11 May 2023 Edesa Biotech intends to obtain marketing approval for paridiprubart for the treatment of acute respiratory distress syndrome (ARDS) and and other conditions that involve dysregulated innate immune responses like systemic sclerosis